Hansa

Turning a research company into a fully integrated, commercial-stage biopharmaceutical company

Hansa Biopharma is a Swedish biotechnology company focused on harnessing the power of a first-of-its-kind IgG-cleaving enzyme that has the potential to prevent rejection of a transplant.  In other words, it is conceivable that any patient could accept any organ, regardless of it being a match or not.

The Challenge

Given the enormity of this breakthrough and global impact of this opportunity, there remained many steps to complete before commercialization could be realized.

We set out to create the Hansa brand, vision, and value proposition, in order to:

  1. Build global awareness and generate interest among institutional investors.

  2. Establish relationships with global kidney and transplant NGOs, and patient advocacy organizations

The Insight

Many biotech companies focus on diseases with large and, therefore, profitable patient populations. They discover proprietary products and market them to the world. There are three ways that Hansa is different.

 The Hansa brand focuses on rare people, not rare diseases.

  1. They PARTNER with the global scientific, medical, and patient communities to create products that satisfy unique medical needs

  2. Their advanced technology PLATFORM produces lifesaving products and therapies

  3. They PARTICIPATE in the global community by returning value to society at large by reducing the costs of long-term care

Identity and Promise

The Hansa symbol is an expression of optimism and inspiration. It can be interpreted as a sunrise, a molecule, a community, or a bloom. The symbol rises above the logotype, signifying a promising, new day.

The Value Proposition

“We will eliminate rare diseases one person at a time. And we won’t stop until we do.”

Creative Strategy

People with unique needs are often overlooked.  Outliers are left behind, and those with rare conditions are too frequently left to fight for themselves because when developing new therapies, success comes from focusing on the forest, that is, medicines that target large global populations.

At Hansa Biopharma, we view things differently.  We realize that forests are made up of trees—those patients who are distinct individuals with unique needs. That's why we focus on rare patients rather than rare diseases.   So, what have we learned?  That curing one tree at a time will soon heal the forest.  All of this inspires our confidence that ultimately Hansa can—and will—eliminate rare diseases one person at a time.  And we won't stop until we do.

The Result

Hansa Biopharma has successfully transitioned from a research company to a fully integrated commercial pharmaceutical company.  Hansa achieved Great Place to Work[®] certification for the third consecutive year.  Hansa’s first commercial product, Imlifidase, was launched across Europe in 2020 and remains the first and only product for the desensitization of highly sensitized patients prior to kidney transplantation.

Prix Galien awarded to Hansa with the 2022 Pharmaceutical Award for Scientific Breakthrough.